Omya International will be moving its research and development activities to Egerkingen after the acquisition of the Galderma-Spirig site.
The buildings in Egerkingen have a modern technical infrastructure, which are suitable for research and development activities without substantial structural interventions. The Cosmospheres business unit, which Omya intends to acquire, would complement and expand Omya’s offering, as Omya already is a supplier of raw materials for the cosmetics and pharmaceutical industries.
In September 2017, Nestlé announced that it would be closing its Galderma-Spirig site in Egerkingen. This site will now be given a new lease of life by Omya International, which is based in neighbouring Oftringen AG. It will take on the property in full, including all buildings and facilities, Omya International revealed in a press release. The producer of industrial minerals will be moving all research and development activities here. In addition, Omya intends to acquire the Cosmospheres business unit from Spirig Pharma.
Spirig is part of Nestlé Skin Health S.A. and is primarily engaged in the field of dermatics.
Omya is a leading global producer of industrial minerals – mainly fillers and pigments derived from calcium carbonate and dolomite – and a worldwide distributor of specialty chemicals. The company provides a wealth of product solutions that contribute to its customers’ competitiveness and productivity in multiple industries such as Construction, Printing & Writing, Technical Polymers, Packaging, Food, Personal & Home Care, Pharmaceuticals, Agriculture and Forestry, Water and Energy.
Walder Wyss advised Spirig Pharma with respect to this transaction with a team led by Nicolas Iynedjian (Corporate/Real Estate, in picture) and Jan Ole Luuk (Tax).
Law Firms: Walder Wyss Ltd.;
Clients: Spirig Pharma;